Reflects the weighted average price of 345,765 shares of common stock of SkyWater Technology, Inc. sold in multiple transactions on August 12, 2025 with sale prices ranging from $12.53 to $13.44 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price

Mr. Unterseher is President of CMI Oxbow Partners, LLC ("CMI") and Managing Partner of Oxbow Industries, LLC ("Oxbow"), which is the majority member of CMI. CMI directly holds the shares of Common Stock reported in Column 5. As a result, he may be deemed to be the beneficial owner of, and to have a pecuniary interest in, such shares of Common Stock. Mr. Unterseher disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

Reflects the weighted average price of  287,454 shares of common stock of SkyWater Technology, Inc. sold in multiple transactions on August 13, 2025 with sale prices ranging from $12.115 to $12.76 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price

Oxbow directly holds the shares reported in Column 5.

Shares owned directly by Mr. Unterseher.


Held by the Heather Hasson Revocable Trust

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

These Restricted Stock Units ("RSUs") vest as to 1/16th of the shares of Class A Common Stock underlying the RSUs on each quarterly anniversary following August 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

947,868 of these securities are RSUs, each representing a contingent right to receive one share of the Issuer's Class A Common Stock. In addition to the securities reported in this column, the Reporting Person holds 2,814,480 shares of the Issuer's Class B Common Stock directly and indirectly through various trusts, which are convertible at any time at the option of the Reporting Person into an equal number of shares of Class A Common Stock,  and 11,449,396 shares of the Issuer's Class A Common Stock underlying vested options, neither of which are reported on this Form 4.

The Reporting Person is a managing member of Hollywood Capital Partners LLC and disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

All shares underlying this option have vested.

The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 12, 2025 (the "Repricing Date"). The Option Repricing applies to (i) 727,097 fully vested options originally granted to the Reporting Person on May 26, 2021 with an original exercise price of $22.00 and (ii)  2,863,828 fully vested options originally granted to the Reporting Person on August 9, 2022 with an original exercise price of $11.79. Pursuant to the Option Repricing, the exercise prices of the repriced options have been amended to reduce the exercise price to $6.63 per share, the closing price of the Issuer's Class A Common Stock on the Repricing Date. The vesting schedules of the repriced options have also been extended as reported herein. There is no change to the expiration dates of, or number of shares underlying, the repriced options. For more information, see Part II, Item 5. "Other Information" in the Issuer's Form 10-Q filed with the SEC on 8/7/2025.

The option vests and becomes exercisable in 24 equal monthly installments, with the first installment vesting on September 12, 2025.

The option vests and becomes exercisable in 48 equal monthly installments, with the first installment vesting on September 12, 2025.

/s/ Danielle Warner as Attorney-in-Fact for Heather Hasson


Common Stock

Represents shares relinquished by the Reporting Person in exchange for the Issuer's payment of federal and state tax withholding obligations of the Reporting Person resulting from the vesting of RSUs, in accordance with Rule 16b-3.

Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

The restricted stock units vest as to 1/16th of the total shares quarterly, with the first vesting having occurred on May 12, 2022, and subject to the continued service of the Reporting Person on each vesting date.

/s/ William R. McDermott by Russell S. Elmer, Attorney-in-Fact


Series C Liberty Formula One Common Stock

/s/ Brittany A. Uthoff as Attorney-in-Fact for Andrea L. Wong


These shares were issued to the reporting person as part of his compensation for service as a director of the registrant.

/s/ BY: JERRY C. JONES, ATTORNEY-IN-FACT FOR: CHARLES BRIAN O'KELLEY


Common Stock

/s/ Paul Fipps by Russell S. Elmer, Attorney-in-Fact


Represents a grant of restricted stock units pursuant to the Issuer's 2021 Omnibus Incentive Plan. Each restricted stock unit represents the right to receive, upon vesting, one share of Common Stock. These restricted stock units will vest in equal, or nearly equal, installments on August 12 of each of 2026, 2027, and 2028, subject to the reporting person's continuous employment through such date.

/s/ Carly Kennedy, Attorney-In-Fact for Jesse Weaver


Class A Common Stock

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A common stock.

One-third of the RSUs vested on May 12, 2025. The remainder of the RSUs vest in equal quarterly installments such that they will be fully vested on May 12, 2027. The RSUs do not have an expiration date.

The numbers of shares (including shares underlying RSUs) reported on this Form 4 have been adjusted to give effect to a 1-for-20 reverse stock split of the Issuer's Class A and Class B common stock that was effected on August 5, 2025.


Common Stock

The restricted stock units vest as to 1/16th of the total shares quarterly, with the first vesting having occurred on May 12, 2022, and subject to the continued service of the Reporting Person  on each vesting date.


Common Shares

The option was granted on March 15, 2022 and vests in three equal annual installments beginning March  15, 2023.

/s/ Maria Teresa Punsalan, attorney-in-fact for James J. Jeter


By Melvin Sharoky C/F Owen F. Paley UTMA/FL

By Melvin Sharoky C/F Nolan M. Wink UTMA/FL

By Melvin Sharoky C/F Wren J. Sharoky UTMA/FL

By Melvin Sharoky C/F Tulia L. Sharoky UTMA/FL

By Melvin Sharoky C/F Adler J. Wink UTMA/FL

By Melvin Sharoky C/F Leo J. Sharoky UTMA/FL

By Melvin Sharoky C/F Sophie C. Wink UTMA/FL

By Melvin Sharoky C/F Violet A. Paley UTMA/FL

The Reporting Person is a managing member of Baby Gator LLC.

Represents a gift of securities by the Reporting Person to his spouse.

The Reporting Person is the custodian of Melvin Sharoky C/F Owen F. Paley UTMA/FL.

The Reporting Person is the managing member of Padonia, LLC.

The Reporting Person is Chairman of The Sharoky Family Foundation, Inc. and is one of three individuals who currently share voting and investment power over the shares held by The Sharoky Family Foundation, Inc. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

The Reporting Person is the custodian of Melvin Sharoky C/F Nolan M. Wink UTMA/FL.

The Reporting Person is the custodian of Melvin Sharoky C/F Wren J. Sharoky UTMA/FL.

The Reporting Person is the custodian of Melvin Sharoky C/F Tulia L. Sharoky UTMA/FL.

The Reporting Person is the custodian of Melvin Sharoky C/F Adler J. Wink UTMA/FL.

The Reporting Person is the custodian of Melvin Sharoky C/F Leo J. Sharoky UTMA/FL.

The Reporting Person is the custodian of Melvin Sharoky C/F Sophie C. Wink UTMA/FL.

The Reporting Person is the custodian of Melvin Sharoky C/F Violet A. Paley UTMA/FL.

Exhibit List - Exhibit 24 - Power of Attorney

/s/ Melvin Sharoky, M.D, by Michael A. Smith as Attorney-in-fact


The sale transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2024.

/s/ Christopher M. Forrester, Attorney-in-Fact


On August 13, 2025, the Reporting Person received an award agreement effective as of April 30, 2025 granting Restricted Stock Units equal to 1,000,000 shares of Common Stock, which will vest in three equal installments on each of the first three anniversaries of the award date.


On August 13, 2025, the Reporting Person received an award agreement effective July 1, 2025 for Restricted Stock Units (RSUs) equal to 552,927 shares of Common Stock, par value $0.01 per share of Patriot National Bancorp, Inc. (the Issuer). The RSUs were granted pursuant to an Employment Agreement between the Reporting Person and the Issuer, effective as of March 20, 2025.  The RSUs vest in 12 equal monthly installments commencing on July 1, 2025 and ending on July 1, 2026. Vested RSUs represent the right to be settled on July 1, 2026.


On August 7, 2025, the Reporting Person received an award agreement effective as of April 30, 2025 granting Restricted Stock Units equal to 450,000 shares of Common Stock, which will vest in three equal installments on each of the first three anniversaries of the award date.


By Steven and Ainslie Sugarman Living Trust

Non-Voting Common Stock

Non-Voting Common Stock

On March 20, 2025, Patriot National Bancorp, Inc. (the Issuer) completed its private placement of: (i) shares of Common Stock, par value $0.01 per share of the Issuer (the Voting Common Stock) at a purchase price of $0.75 per share, and (ii) shares of a new series of the Issuer's preferred stock, no par value per share (the Series A Preferred Stock), with a liquidation preference of $60 per share (the Private Placement). Steven and Ainslie Sugarman Living Trust (the Trust) purchased, as part of the Private Placement, 19,167 shares of Series A Preferred Stock, convertible into 1,533,333 shares of Voting Common Stock, subject to the limitation that no investor in the Private Placement has the right to become the beneficial owner (as determined under Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the Exchange Act)) of more than 9.99% of the issued and outstanding voting securities of the Issuer.

On July 3, 2025, all issued and outstanding shares of Series A Preferred Stock automatically converted into shares of non-voting common stock, par value $0.01 per share ("Non-Voting Common Stock"), of the Issuer, pursuant to the terms of the Amended and Restated Certificate of Incorporation of the Issuer. Series A Preferred Stock had no expiration date. Each share of Non-Voting Common Stock is convertible into one share of Voting Common Stock, subject to the terms of the Amended and Restated Certificate of Incorporation of the Issuer, including the limitation that no holder of Non-Voting Common Stock has the right to become the beneficial owner (as determined under Rule 13d-3 under the Exchange Act) of more than 9.99% of the issued and outstanding voting securities of the Issuer. Voting Common Stock has no expiration date.

The Trust is a revocable living trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are the trustees of the Trust.

The Trust was also issued 5,833 shares of Series A Preferred Stock, convertible into 466,667 shares of Common Stock, as a reimbursement of the Reporting Person's legal fees and expenses relating to the Private Placement, subject to the limitation that the Reporting Person does not have the right to become, directly or indirectly, the beneficial owner of more than 9.99% of the issued and outstanding voting securities of the Issuer.


Class A Common Stock

Class A Common Stock

Represents the conversion of Class B Common Stock held of record by The Brian Armstrong Living Trust into Class A Common Stock.

The transactions reported on this line were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2024, during an open trading window.

Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

Represents the weighted average sale price. The lowest price at which shares were sold was $324.33 and the highest price at which shares were sold was $325.32. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.

Represents the weighted average sale price. The lowest price at which shares were sold was $325.35 and the highest price at which shares were sold was $326.31.

Represents the weighted average sale price. The lowest price at which shares were sold was $326.36 and the highest price at which shares were sold was $327.325.

Represents the weighted average sale price. The lowest price at which shares were sold was $327.34 and the highest price at which shares were sold was $328.25.

Represents the weighted average sale price. The lowest price at which shares were sold was $329.03 and the highest price at which shares were sold was $329.315.

Represents the weighted average sale price. The lowest price at which shares were sold was $329.345 and the highest price at which shares were sold was $329.52.

These shares are held by The Ehrsam 2014 Irrevocable Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

/s/ Brian Armstrong, by Lailey Rezai, Attorney-in-Fact


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.83 to $5.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4.

/s/ Sean Ricker as Attorney-in-Fact for Dorothy D. Hayes


The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2025.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.82 to $8.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

/s/ Joshua B. Cohen, as Attorney in Fact


This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025.

This transaction was executed in multiple trades during the day at prices ranging from $158.06 to $158.40. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Shares are held by CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust.

This transaction was executed in multiple trades during the day at prices ranging from $159.25 to $160.15. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $162.42 to $163.39. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $160.25 to $161.24. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $156.91 to $157.90. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $163.42 to $164.07. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $161.41 to $162.40. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

/s/ Veena Bhatia, Attorney-in-Fact for Cannon-Brookes Michael


Class A Common Stock

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A common stock.

One-third of the RSUs vested on May 12, 2025. The remainder of the RSUs vest in equal quarterly installments such that they will be fully vested on May 12, 2027. The RSUs do not have an expiration date.


Common Shares

Common Shares

Common Shares

Reporting person sold Common Shares at an average price of $38.1511 of which the Common Shares were sold in multiple transactions at prices ranging from $37.705 and $38.78. The reporting person undertakes to provide to the SEC, the Issuer and any security holder, the full information regarding the number of shares and the prices at which the shares were sold.

Reporting person had an intra-plan transfer of funds between the TDS Common Stock fund and another plan fund in the TDS 401(k) plan.  The number of shares held in the TDS 401(k)  Common Stock funds fluctuates and was attributable to the price of the shares on 8/13/25.

Granted under the Long-Term Incentive Plan.  Stock options were vested.


The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $38.71 to $39.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in this footnote.

/s/ Jonathan Stone, Attorney-in-Fact for Frederic Moll


Tranche A Common Share Purchase Warrants

Common Shares

Tranche B Common Share Purchase Warrants

Common Shares

Tranche C Common Share Purchase Warrants

Common Shares

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.

This amendment is being filed to report that the price at which the Tranche A purchase warrants, Tranche B purchase warrants and Tranche C purchase warrants were exercised was inadvertently disclosed as $0.83158 instead of $0.83518.

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.

On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83518 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.

The Issuer's Form 10-Q filed on August 13, 2025 provides that as of such date, the Issuer had 51,806,497 Common Shares outstanding. Based on this number and other shares included in the denominator of the calculation of the Reporting Person's ownership, the Reporting Person's ownership has dropped below 10% as of the date of filing this amended Form 4. However, based on the publicly available number of outstanding shares reported prior to when this Form 4 was originally filed, the Reporting Person held more than 10% at such time the Form 4 was originally filed.

Title 19 Promis By: /s/ Michael S. Gordon, Manager


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Includes shares acquired through employee stock plans, shares purchased with reinvested dividends and restricted stock units as of August 13, 2025.

The options vest in four equal annual installments (based on the original grant amount) beginning on the date indicated in this column.

/s/ Nicole V. Gersch, on behalf of Corey R. Bailey through Power of Attorney


This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2025.

Shares are held by Farquhar Investment Partnership No. 2.

This transaction was executed in multiple trades during the day at prices ranging from $156.91 to $157.90. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $158.06 to $158.40. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $159.25 to $160.15. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $162.42 to $163.39. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $160.25 to $161.24. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $163.42 to $164.07. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

/s/ Veena Bhatia, Attorney-in-Fact for Farquhar Scott


These shares were issued to the reporting person as part of his compensation for service as a director of the registrant.

/s/ BY: JERRY C. JONES, ATTORNEY-IN-FACT FOR: TIMOTHY R. CADOGAN


Common Shares

Common Shares

Common Shares

By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.


Represents a grant of restricted stock units pursuant to the Issuer's 2021 Omnibus Incentive Plan. Each restricted stock unit represents the right to receive, upon vesting, one share of Common Stock. These restricted stock units will vest in equal, or nearly equal, installments on August 12 of each of 2026, 2027, and 2028, subject to the reporting person's continuous employment through such date.

Each performance stock unit represents a contingent right to receive, upon vesting, one share of Common Stock. The performance rights vest subject to the Common Stock achieving a specified price target on each trading day for a period of twenty (20) consecutive trading days, before the expiration date, on the seven year anniversary of the date of grant.

/s/ Carly Kennedy, Attorney-In-Fact for Matthew J. Stevenson


Class A Common Stock

Class A Common Stock

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A common stock.

Represents shares sold pursuant to a mandatory "sell to cover" provision of the RSU agreement to satisfy tax withholding obligations arising in connection with the vesting and settlement of the RSUs.

Represents the weighted average sale price of multiple transactions at prices ranging from $17.47 to $17.47 per share. The reporting person undertakes to provide, upon request from the staff of the SEC, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents shares sold to satisfy obligations pursuant to a domestic relations order.

One-third of the RSUs vested on May 12, 2025. The remainder of the RSUs vest in equal quarterly installments such that they will be fully vested on May 12, 2027. The RSUs do not have an expiration date.

One-third of the RSUs vested on November 12, 2023. The remainder of the RSUs vest in equal quarterly installments such that they will be fully vested on November 12, 2025. The RSUs do not have an expiration date.


Pursuant to Company policy, market transactions in Company stock by officers and directors are permitted only after the first full trading day after the release of quarterly earnings and ending on the fourteenth day of the third month of the following fiscal quarter, except pursuant to approved 10b5-1 trading plans.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.21 to $77.22, inclusive. The reporting person undertakes to provide NIKE, Inc., any security holder of NIKE, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote (2) to this Form 4.

Includes shares acquired pursuant to NIKE, Inc.'s Employee Stock Purchase Plan.

Shares held in account under the NIKE, Inc. 401(k) Savings and Profit Sharing Plan.

/s/ Kelsey A. Baldwin, attorney-in-fact for Mr. McCartney


Shares were forfeited in connection with the vesting of Restricted Stock Units granted to the reporting person on August 12, 2022.


Common Stock

Transaction is a cash exercise by the reporting person.

The option is fully vested and exercisable.

/s/ Jonathan Stone, Attorney-in-Fact for Alaleh Nouri


Benjamin and Divya Silbermann Family Trust

Class A Common Stock

Class A Common Stock

Class A Common Stock

Represents the conversion of shares of Class B Common Stock, par value $0.00001 ("Class B Common Stock") into Class A Common Stock, par value $0.00001 ("Class A Common Stock"), in connection with the sale of such shares pursuant to a Rule 10b5-1 trading plan.

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2024.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $34.8200 to $35.4200 per share. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Mr. Silbermann disclaims beneficial ownership of the shares held by the SFTC, LLC, a Delaware limited liability company owned by The Silbermann 2012 Irrevocable Trust. This report shall not be deemed an admission that he is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in such shares by virtue of certain of his immediate family members' interests in The Silbermann 2012 Irrevocable Trust.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $34.8200 to $35.4100 per share. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Represents previously reported RSUs that are subject to vesting requirements.

Each share of Class B Common Stock is convertible at any time at the option of the holder into one share of the Class A Common Stock. Additionally, each share of Class B Common Stock will, subject to certain exceptions, convert automatically into one share of Class A Common Stock upon any transfer,  and in other circumstances as outlined in the Issuer's Certificate of Incorporation.


/s/ Stephen Chen, as Attorney-in-Fact for Matthew Skaruppa


On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies.

By Title 19 Acies, of which the Reporting Person was the sole manager.

By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.

The Issuer's Form 10-Q filed on August 13, 2025 provides that as of such date, the Issuer had 51,806,497 Common Shares outstanding. Based on this number and other shares included in the denominator of the calculation of the Reporting Person's ownership, the Reporting Person's ownership has dropped below 10% as of the date of filing this late Form 4. However, based on the publicly available number of outstanding shares reported prior to when this Form 4 was due, the Reporting Person held more than 10% at such time the Form 4 was due.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Represents shares of common stock of the Issuer received on December 21, 2023, as consideration pursuant to that certain Merger Agreement, dated as of June 27, 2023 (as amended on September 22, 2023 and as may be further amended and/or restated from time to time, the "Merger Agreement"), by and among Airship AI Holdings, Inc., a Delaware corporation (the "Issuer") (formerly known as BYTE Acquisition Corp., a Cayman Island exempted company limited by shares, prior to its domestication as a Delaware corporation), BYTE Merger Sub, Inc., a Washington corporation and a direct, wholly-owned subsidiary of the Issuer, and Airship AI, Inc., a Washington company (formerly known as Airship AI Holdings, Inc., "Airship AI"). The Reporting Person received the reported shares in exchange for shares of common stock of Airship AI at the Conversion Ratio, as defined in the Merger Agreement, as of the Effective Time of the Merger.

Airship Kirkland Family Limited Partnership is the record holder of the securities reported herein. Victor Huang is the managing partner of Airship Kirkland Family Limited Partnership and as such has voting and dispositive power over these securities. Mr. Huang disclaims beneficial ownership of the securities held by Airship Kirkland Family Limited Partnership, except to the extent of his pecuniary interest therein.

Represents options to purchase shares of common stock of the Issuer received on December 21, 2023, pursuant to the Merger Agreement, upon the conversion of options to purchase shares of common stock of Airship AI at the Conversion Ratio, as defined in the Merger Agreement, as of the Effective Time of the Merger.

Represents stock appreciation rights denominated in shares of common stock of the Issuer received on December 21, 2023, pursuant to the Merger Agreement, upon the conversion of stock appreciation rights denominated in shares of common stock of Airship AI at the Conversion Ratio, as defined in the Merger Agreement, as of the Effective Time of the Merger.

Represents warrants to purchase shares of common stock of the Issuer received by the Reporting Person on December 21, 2023, pursuant to the Merger Agreement, upon the conversion of warrants to purchase shares of common stock of Airship AI at the Conversion Ratio, as defined in the Merger Agreement, as of the Effective Time of the Merger.

Pursuant to earnout provisions in the Merger Agreement, the holder of such Earnout Rights is entitled to receive shares of common stock of the Issuer upon the occurrence of certain operating performance and share price performance milestones during the applicable earnout periods set forth in the Merger Agreement.

Options vest quarterly over 4 years.

The Reporting Person files this Amendment No. 1 to its original Form 4 dated 01/07/2025 to correctly reflect the transaction and ending balance.


The shares reported herein were granted on August 12, 2025, in the form of restricted stock units ("RSUs"). 10,578 of the RSUs will vest on September 29, 2025, 17,551 will vest on December 31, 2025 and 17,551 will vest on March 31, 2026.

/s/ Jiajun Lu, Attorney-in-fact for Margaret Shan Atkins


The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2024.

This transaction was executed in multiple trades at prices ranging from $40.84 to $41.81. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

This transaction was executed in multiple trades at prices ranging from $41.84 to $42.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

/s/ Shanti Ariker pursuant to power of attorney


Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. The Reporting Person is the Managing Member of GP I. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.


The shares of Common Stock were sold pursuant to a 10b5-1 plan adopted by the Reporting Person on December 11, 2024.


Represents a sale of shares of common stock to satisfy tax obligations.

/s/ Michael A. Sherrick, Attorney-in-Fact


William E. Matthews, V, CFO, pursuant to power of attorney


These shares were acquired under the Corporation's 2017 Plan for Non-Employee Directors in lieu of quarterly board retainer fees of $10,483.35.

/s/ Steven M. Bradford;                      by Power of Attorney


These shares were issued to the reporting person as part of his compensation for service as a director of the registrant.

/s/ BY: JERRY C. JONES, ATTORNEY-IN-FACT FOR: CLARK M. KOKICH


Common Stock

Each share of phantom stock is the economic equivalent of one share of common stock and becomes payable in cash following the reporting person's termination of service as an officer. The reporting person may transfer his phantom stock account into an alternative investment account at any time.

Phantom stock acquired upon (1) deferral of compensation under the PG&E Corporation 2005 Supplemental Retirement Savings Plan and (2) credits awarded to the reporting person's account under the PG&E Corporation Defined Contribution Executive Supplemental Retirement Plan, each exempt under Rule 16b-3(d).

This total includes 17.14 units of phantom stock acquired on 4/15/2025 and 22.65 units of phantom stock acquired on 7/15/2025 pursuant to a dividend reinvestment feature of the PG&E Corporation 2005 Supplemental Retirement Savings Plan and the PG&E Corporation Defined Contribution Executive Supplemental Retirement Plan.

/s/ J. Ellen Conti, attorney-in-fact for Kaled Awada (Signed Power of Attorney on file with SEC)


Common Stock

Restricted stock units that vest three years from the date of grant and are settled in shares of Applied common stock.

Performance shares "banked" as a result of 2025 performance. Performance shares vest at end of three-year program and are settled in shares of Applied common stock.

Shares withheld by Registrant to satisfy tax withholding obligations on vesting of performance shares.

Stock-only stock appreciation rights which become exercisable in annual increments of 25% commencing one year after the date of grant.

/s/Patricia A. Comai POA for Neil A. Schrimsher


The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of the Reporting Person's pecuniary interest therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

/s/ Jonathan Groff for Ralph Alvarez, pursuant to authorization on file


The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.00 through $66.01 per share, inclusive. The Filer undertakes to provide Independent Bank Corp., any security holder of Independent Bank Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.50 through $67.58 per share, inclusive. The Filer undertakes to provide Independent Bank Corp., any security holder of Independent Bank Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

Shares held in Filer's name f/b/o daughter. Holdings include 2.4283 shares received pursuant to the Independent Bank Corp. 2014 Dividend Reinvestment and Stock Purchase Plan since the last Form 4 filing (07/03/2025). Such transactions are exempt from the reporting requirements of Section 16 of the Securities and Exchange Act of 1934, as amended. The filing of this statement should not be construed as an admission that the Filer is, for purposes of Section 16 of the Exchange Act, the beneficial owner of such securities.

Shares held in Filer's name f/b/o son. Holdings include 2.4497 shares received pursuant to the Independent Bank Corp. 2014 Dividend Reinvestment and Stock Purchase Plan since the last Form 4 filing (07/03/2025). Such transactions are exempt from the reporting requirements of Section 16 of the Securities Exchange Act of 1934, as amended. The filing of this statement should not be construed as an admission that the Filer is, for purposes of Section 16 of the Exchange Act, the beneficial owner of such securities.

/s/ Maureen A. Gaffney, Power of Attorney for Gerard F. Nadeau


Common Stock

Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.


Common Stock


Common Stock

Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of XOMA common stock.  The PSUs vest upon XOMA's common stock achieving a specified price per share.

/s/ Thomas Burns, Attorney-in-Fact for Maricel Perea Montano


The reporting person sold 65,395 Common Shares at an average price of $75.76 and 27,905 Common Shares at an average price of $75.7952 in which shares were sold in multiple transactions at prices ranging from $75.62 and $76.18. The reporting person undertakes to provide to the SEC, the Issuer and any security holder, the full information regarding the number of shares and the prices at which the shares were sold.


The price reported in Column 4 is the share price on August 12, 2025.  The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold as set forth in this footnote.


Shares were sold to cover the taxes from restricted stock units that vested on February 10, 2025.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.65 to $5.6983, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.


The sale was effected by Mr. Painter pursuant to a rule 10b5-1 sale plan effective February 20, 2025.


Common Shares

Common Shares

Common Shares

There was 12,475.377 Common Shares sold at an average price of $38.50.  Additionally, there was 29,517 Common Shares sold at an average price of $38.684 of which the shares were sold in multiple transactions at prices ranging from $38.595 and $38.96. The reporting person undertakes to provide to the SEC, the Issuer and any security holder, the full information regarding the number of shares and the prices at which the shares were sold.  The total number of shares sold includes 14 shares acquired through dividend reinvestment.

Granted under the Telephone and Data Systems, Inc. Long-Term Equity Plan.  Option is currently exercisable.


Gifts.


Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2021 Equity Incentive Plan. Each RSU represents the conditional right to receive one share of Common Stock. The RSUs will vest in full on the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. The Reporting Person is an employee of Anthos Management LP (the "Management Company"). The Reporting Person holds the reported RSUs for the benefit of the Management Company. The Management Company is an affiliate of Anthos Capital IV and Anthos Tribe (each as defined below) and is managed by Paul Farr and Bryan Kelly. The Reporting Person is the spouse of Mr. Kelly. The Reporting Person disclaims beneficial ownership of the RSUs, except to the extent of her pecuniary interest therein.

Shares are held by Anthos Capital IV, L.P. ("Anthos Capital IV"). Anthos Associates IV, L.P. ("Anthos Associates IV") is the general partner of Anthos Capital IV and Anthos Associates GP IV, LLC ("Anthos Associates GP IV") is the general partner of Anthos Associates IV. Paul Farr and Bryan Kelly are the sole managers of Anthos Associates GP IV. The Reporting Person is the spouse of Mr. Kelly and as a result also may be deemed to have beneficial ownership of the shares held directly by Anthos Capital IV. The Reporting Person disclaims beneficial ownership of the shares held by Anthos Capital IV, except to the extent of her pecuniary interest, if any, therein.

Shares are held by Anthos Tribe, L.P. ("Anthos Tribe"). Anthos Tribe GP, LLC ("Anthos Tribe GP") is the general partner of Anthos Tribe. Paul Farr and Bryan Kelly are the sole managers of Anthos Tribe GP. The Reporting Person is the spouse of Mr. Kelly and as a result also may be deemed to have beneficial ownership of the shares held directly by Anthos Tribe. The Reporting Person disclaims beneficial ownership of the shares held by Anthos Tribe, except to the extent of her pecuniary interest, if any, therein.

Shares are held by the Management Company. The Management Company is an affiliate of Anthos Capital IV and Anthos Tribe, and is managed by Paul Farr and Bryan Kelly. The Reporting Person is the spouse of Mr. Kelly and as a result also may be deemed to have beneficial ownership of the shares held directly by the Management Company. The Reporting Person disclaims beneficial ownership of the shares held by the Management Company, except to the extent of her pecuniary interest, if any, therein.


Includes shares purchased pursuant to the Employee Stock Purchase Plan.

/s/ Dara Steele-Belkin, attorney-in-fact for David Sheffield


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.85, inclusive.

Includes 28,606 restricted stock units ("RSUs") granted on December 27, 2024 to non-employee directors for board service. The RSUs represent a contingent right to receive shares of common stock of Applied Digital Corporation on a one-for-one basis, have no expiration date, and vest in full on November 20, 2025, subject to the Reporting Person's continued service through such date.


Common Stock

Common Stock

Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer.

The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer.

Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options.

The restricted stock units were deemed vested aod settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share.


Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2021 Equity Incentive Plan. Each RSU represents the conditional right to receive one share of Common Stock. The RSUs will vest in full on the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.


These shares were issued to the reporting person as part of his compensation for service as a director of the registrant.

/s/ BY: JERRY C. JONES, ATTORNEY-IN-FACT FOR: JOHN L. BATTELLE


Common Stock, par value $0.001 per share ("Common Stock")

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at a price of $5.50 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares bought at each price.

Represents securities owned directly by Mink Brook Partners LP (the "Fund"). As the investment manager of the Fund, Mink Brook Asset Management LLC may be deemed to beneficially own the securities owned directly by the Fund.

Mink Brook Asset Management LLC, and the general partner for both funds, Mink Brook Capital GP LLC, disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Mink Brook Asset Management LLC, Mink Brook Capital GP LLC or William Mueller as managing member of both, is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Represents securities owned directly by Mink Brook Opportunity Fund LP (the "Fund"). As the investment manager of the Fund, Mink Brook Asset Management LLC may be deemed to beneficially own the securities owned directly by the Fund.


Common Stock

The restricted stock units were deemed vested and settled on the date of the liquidation distribution, and such settled shares received a liquidation distribution of $5.35 per share.


The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.


Common Stock


The total amount of holdings reflects an acquisition on May 30, 2025 of 122 shares through the Issuer's Employee Stock Purchase Plan which is exempt under Rule 16b-3(c).

/s/ Katherine M. Serevitch, Attorney-in-Fact


The balance has been updated to no longer include 84.69 shares of phantom stock in the Savings Restoration Plan that have historically been reported in Table I but instead were reportable in Table II. Each share of phantom stock that was acquired under the Savings Restoration Plan is the economic equivalent of one common share and is settled in cash. The shares of phantom stock generally become payable following the reporting person's separation from service

/s/ Stephanie R. Breitenbach, Attorney-In-Fact


Common Stock

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.07 to $78.77. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.05 to $79.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.05 to $79.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

The Stock Options vested in four equal annual installments on the first four anniversaries of the grant date, beginning on January 5, 2019.


Represents shares of Common Stock of Gryphon Digital Mining, Inc. (the "Issuer") issuable upon settlement of Restricted Stock Units ("RSUs") that were forfeited as a result of the reporting person resigning as a director of the Issuer.

Represents shares of Common Stock of the Issuer issuable upon settlement of RSU.

The reporting person resigned as a director of the Issuer effective June 12, 2025. As a result, the reporting person is no longer subject to Section 16 in connection with his transactions in the equity securities of the Issuer and therefore will no longer report any such transactions on Form 4 or Form 5.


Shares issued under the Capital Southwest 2021 Non-Employee Director Restricted Stock Award Plan

These securities are held by FMAB Partners, LP, a limited partnership controlled by the reporting person provided that the reporting person holds 50% of the membership interest in the sole general partner of FMAB Partners, LP. The reporting person disclaims beneficial ownership of the reported shares of common stock except to the extent of his pecuniary interest therein.


This sale was effected pursuant to the terms of a Rule 10b5-1 trading plan adopted by the Reporting Person on May 2, 2025.

The number of shares of KLA common stock includes 10,902.905 shares issuable upon vesting of restricted stock units ("RSUs").

/s/ Jeffrey S. Cannon, as attorney-in-fact for Brian Lorig


This transaction was executed in multiple trades at prices ranging from $5.56 to $5.995. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Includes 409 shares acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.

This transaction was executed in multiple trades at prices ranging from $6.485 to $6.735. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Teresa Bair, Attorney-in-fact for Troy E. Wilson


This sale was effected pursuant to the terms of a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2024.

The number of shares of KLA common stock includes 57,511.168 shares issuable upon vesting of restricted stock units ("RSUs").

This gift was effected pursuant to the terms of a Rule 10b5-1 trading plan adopted by the Reporting Person on November 1, 2024.

/s/ Jeffrey S. Cannon, as attorney-in-fact for Richard P. Wallace


The reported price represents the volume-weighted average price of shares sold. Sale prices for the reported transaction ranged between $108.97 and $112.19. Full information regarding the number of shares sold at each price in the range will be provided to the SEC upon request.

/s/ Cot Eversole, Attorney-in-Fact for Randy Lake


Common Stock

Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer.

The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer.

Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options.


/s/ BY: JERRY C. JONES, ATTORNEY-IN-FACT FOR: LAUREN R. DILLARD


By the Amended and Restated John P. Bilbrey Revocable Declaration of Trust

Represents restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2021 Equity Incentive Plan. Each RSU represents the conditional right to receive one share of Common Stock. The RSUs will vest in full on the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.


The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2025.

/s/ Rachel V. Friedenberg, Attorney-in-Fact for Obed D. Louissaint


On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding  at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time.

Jennifer Guckert Griffin, pursuant to a power of attorney


Common Stock

On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share , of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

As of the Effective Time, each of the shares of the Issuer's Common Stock that the Reporting Person previously reported as beneficially owned under the Issuer's 401(k) plan was converted into the right to receive the Per Share Merger Consideration.

These options are fully vested.

In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) the quotient obtained by dividing the Per Share Merger Consideration by the volume-weighted average of the closing sale price per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date (the "Equity Award Exchange Ratio"), at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option.


Represents number of securities owned by EN Holdings LLC, which is owned by the reporting person and his affiliates.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.76 to $67.75. The Reporting Person undertakes to provide Interactive Brokers Group, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) - (7) to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.76 to $68.04.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.18 to $64.17.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.18 to $65.17.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.18 to $66.17.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.18 to $67.06.

This amount includes (a) Class A common stock attributable to vested restricted stock units that were awarded under the amended 2007 Stock Incentive Plan ("Plan") and (b) unvested restricted stock units that were awarded under the Plan.

/s/ Raymond Bussiere as authorized signatory for Earl H. Nemser


Restricted Stock Unit (Performance-Based Vesting)

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

Pursuant to the Merger Agreement, outstanding restricted stock units ("RSUs") of the Issuer were automatically converted into UnitedHealth Group RSUs, calculated by multiplying the number of Issuer RSUs by the quotient obtained by dividing the Per Share Merger Consideration by the volume-weighted average of the closing sale price per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date (the "Equity Award Exchange Ratio"), which continue to be subject to the same terms and conditions (including vesting and settlement terms) as were applicable to the Issuer RSUs.

The performance-based restricted stock units ("PSUs") were scheduled to cliff vest following a three-year performance period ending December 31, 2025 based on the Company's achievement of Adjusted EBITDA for 2023, as modified by the Company's three-year total shareholder return percentile rank compared to a pre-established comparator group (the "TSR Modifier"). On February 20, 2024, the Compensation Committee of the Issuer's Board of Directors certified achievement of 2023 Adjusted EBITDA performance at 127.23%, thereby resulting in the Reporting Person earning 3,468 PSUs. The amount reported represents 127.23% of the target number of PSUs originally awarded and assumes performance at target (100%) for the TSR Modifier pursuant to the terms of the Merger Agreement.

Pursuant to the Merger Agreement, PSUs of the Issuer were automatically converted into time-based vesting UnitedHealth Group RSUs, with the number of shares of UnitedHealth Group common stock subject to the UnitedHealth Group RSUs equal to (i) the number of shares of Common Stock underlying the Issuer PSUs based on the amount actually earned for the 2023 Adjusted EBITDA performance measure and assuming target performance (100%) for the TSR Modifier, multiplied by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group RSUs will continue to be subject to the same terms and conditions as were applicable to the Issuer PSUs, and will vest on December 31, 2025.

These options are fully vested.

In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) Equity Award Exchange Ratio, at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option.

1,530 of the options are fully vested; 510 of the options are scheduled to vest on February 20, 2026.

1,917 of the options are fully vested; 959 of the options are scheduled to vest on February 20, 2026.

/s/ Jennifer R. Guckert, pursuant to a power of attorney


On August 14, 2025, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Amedisys, Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of June 26, 2023 (as modified by the waiver, dated December 26, 2024, the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Aurora Holdings Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (other than certain excluded shares) automatically converted into the right to receive $101 per share in cash (the "Per Share Merger Consideration"), without interest and less any applicable withholding tax.

Includes 1,690 time-based Restricted Stock Units ("RSUs") of the Issuer that were outstanding  at the Effective Time that were cancelled and converted into the right to receive the Per Share Merger Consideration for each such outstanding RSU as of the Effective Time.


Common Stock

Common Stock

Common Stock

Common Stock

As of the Effective Time, each of the shares of the Issuer's Common Stock that the Reporting Person previously reported as beneficially owned under the Issuer's 401(k) plan was converted into the right to receive the Per Share Merger Consideration.

These options are fully vested.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

The performance-based restricted stock units ("PSUs") were scheduled to cliff vest following a three-year performance period ending December 31, 2025 based on the Company's achievement of Adjusted EBITDA for 2023, as modified by the Company's three-year total shareholder return percentile rank compared to a pre-established comparator group (the "TSR Modifier"). On February 20, 2024, the Compensation Committee of the Issuer's Board of Directors certified achievement of 2023 Adjusted EBITDA performance at 127.23%, thereby resulting in the Reporting Person earning 10,399 PSUs. The amount reported represents 127.23% of the target number of PSUs originally awarded and assumes performance at target (100%) for the TSR Modifier pursuant to the terms of the Merger Agreement.

These options are fully vested.

4,589 of the options are fully vested; 1,530 of the options vest on February 20, 2026.

5,751 of the options are fully vested; 2,876 of the options vest on February 20, 2026.

/s/ Jennifer Guckert Griffin, pursuant to a power of attorney


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

These options are fully vested.


Common Stock

Common Stock

Common Stock

Common Stock

These options are fully vested.


Common Stock

Common Stock

Common Stock

Reflects performance based restricted stock units ("PSUs") granted on April 12, 2023 which were originally scheduled to vest based on the achievement of certain performance criteria determined at the end of a three-year performance period. Pursuant to the Merger Agreement, PSUs of the Issuer were automatically converted into time-based vesting UnitedHealth Group RSUs, with the number of shares of UnitedHealth Group common stock subject to the UnitedHealth Group RSUs equal to (i) the number of shares of Common Stock underlying the Issuer PSUs based on target performance multiplied by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group RSUs will continue to be subject to the same terms and conditions as were applicable to the Issuer PSUs, and will vest on April 12, 2026.

The PSUs were scheduled to cliff vest following a three-year performance period ending December 31, 2025 based on the Company's achievement of Adjusted EBITDA for 2023, as modified by the Company's three-year total shareholder return percentile rank compared to a pre-established comparator group (the "TSR Modifier"). On February 20, 2024, the Compensation Committee of the Issuer's Board of Directors certified achievement of 2023 Adjusted EBITDA performance at 127.23%, thereby resulting in the Reporting Person earning 39,850 PSUs. The amount reported represents 127.23% of the target number of PSUs originally awarded and assumes performance at target (100%) for the TSR Modifier pursuant to the terms of the Merger Agreement.

11,237 of the options are fully vested; the remaining 11,237 options are scheduled to vest on February 20, 2026.


This transaction was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.22 to $19.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.50 to $19.94 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.


The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $18.90 to $19.32, inclusive. The reporting person undertakes to provide CompoSecure, Inc. (the "Issuer"), any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Includes (A) 218,960 shares of Class A Common Stock owned by the reporting person, inclusive of shares previously purchased by the reporting person under the Company's Employee Stock Purchase Plan, (B) 63,251 shares of Class A Common Stock underlying restricted stock units ("RSUs"), which will vest in three equal installments on February 26, 2028, February 26, 2030 and February 26, 2032, (C) 75,000 shares of Class A Common Stock underlying RSUs which will vest on January 1, 2026, (D) 43,658 shares of Class A Common Stock underlying RSUs which will vest on January 1, 2026, (E) 107,129 shares of Class A Common Stock underlying RSUs which will vest ratably on each of January 1, 2026 and January 1, 2027, and (cont'd in FN3)

(con't from FN 2) (F) 291,670 performance-vesting RSUs, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the respective governing award agreement, subject in each case to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into Class A Common Stock upon vesting and may be settled net of shares withheld to pay applicable taxes.

/s/ Amanda Gourbault, by attorney-in-fact Steven J. Feder


Common Shares, no par value ("Common Shares")

Common Shares

Common Shares

Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.

Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.

The option was vested and was exercisable as of the Transaction Date.


These transactions occurred pursuant to broker-dealer sales conducted in accordance with Rule 144 under the Securities Act of 1933, as amended.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.83 to $87.89, inclusive. The Reporting Persons (as defined below) undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.965, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.03 to $89.95, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.99, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.11 to $91.97, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.98, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.005 to $93.98, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.00 to $94.995, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.9975, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.89, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in this footnote.

This report is filed jointly by Weichai America Corp., Weichai Power Co., Ltd. and Shandong Heavy Industry Group Co., Ltd. (collectively, the "Reporting Persons"). Weichai America Corp. is the direct owner of the Common Stock referenced in this report and shares the power to vote and the power to dispose of all of such shares of Common Stock with the other Reporting Persons. No individual has beneficial ownership over the Common Stock beneficially owned by the Reporting Persons.

Exhibit List:

Exhibit 24.1 - Power of Attorney (Weichai Power Co., Ltd.)
Exhibit 24.2 - Power of Attorney (Shandong Heavy Industry Group Co., Ltd.)


This Form 4 is being filed jointly by each of Vladimir Galkin and Angelica Galkin, husband and wife (the "Reporting Persons"). The price reported reflects the actual purchase or sale price (whichever the case may be) for each transaction, unless the applicable footnote specifies the use of a volume weighted average price is used for a range of multiple trade prices. In such instances, the Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price within the ranges set forth in footnotes.

The purchases were executed in multiple trades at prices ranging from $57.50 to $58.85.


/s/ Mark Hueppelsheuser, Attorney-in-Fact for Richard Barasch


Common Stock

Common Stock

Cumulative amount does not include presently unexerciseable options granted in December 2020. Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount currently outstanding is 1,500. For further details, see the Company's proxy statement filed July 3, 2025.


Common Stock

Common Stock


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

The option exercise price increases approximately 10% at each test date and 16.67% of the option grant is available for vesting on each test date. Each option has six test dates, which occur on each subsequent anniversary of the option grant date. For further details see the Company's proxy statement filed July 3, 2025.


Common Stock

Common Stock

Cumulative amount does not include presently unexerciseable options granted in December 2020. Whether any of the unexerciseable options vest, and the amount that does vest, is tied to various price tranches (six per year) corresponding to future testing dates (June 30 of each year) and the achievement of our Common Stock trading at or above the exercise price for each applicable price tranche. In the event that the market price of our common stock does not reach or exceed the exercise price during the 60 days immediately preceding the applicable price tranche, 100% of the applicable options associated with that price tranche expire immediately. After expirations due to failures to reach the prior stated exercise prices, total amount currently outstanding is 15,000. For further details, see the Company's proxy statement filed July 3, 2025.


These represent deferred stock units ("DSU") that were awarded as part of the Company's compensation program for non-management directors in connection with the 2025 annual stockholders' meeting. Each DSU constitutes the right to receive one share of the Company's common stock upon settlement (which occurs when the recipient's service with the Company is concluded). During the remaining term of service, DSUs are nontransferable and carry neither voting nor dividend rights. DSUs are subject to the terms and conditions of the Company's standard form DSU agreement.

Reporting person maintains an indirect interest in these shares insofar as he is Managing Member of Cruiser Capital, which serves as the management company or as investment advisor to, and may be deemed to have shared voting and dispositive power over Common Stock held by, various investment funds (the "Cruiser Funds") and separately managed accounts (the "Cruiser SMAs", together with the Cruiser Funds, the "Cruiser Funds and SMAs") that it advises. Reporting person may be deemed to have voting and dispositive power with respect to the shares of Common Stock held by the Cruiser Funds and SMAs and disclaims beneficial ownership of the securities held by the Cruiser Funds and SMAs except to the extent of his pecuniary interest.


Common Stock

On May 22, 2019 and May 21, 2025, the Common Stock of Fastenal Company split 2-for-1 and the amounts reported have been adjusted to reflect these two stock splits.

Shares attributed to reporting person's account within issuer's 401(K) Plan and includes an additional 124 stock split (May 21, 2025) adjusted securities acquired since the reporting person's previous report on April 28, 2025.

The option will vest and become exercisable over a period of five years, with 40% the option vesting and becoming exercisable two years following the date of grant, and the remainder vesting and becoming exercisable proportionately on each anniversary of the grant date.


Angel Oak Financial Strategies Income Term Trust


The shares are purchased in one transaction at a price given in Column 4.

Mr. Hixon is the sole trustee of the "Dylan Trust under the JMH-ICH Lex Trust" which holds shares in Arden Road Investments LLC. Mr. Hixon may be deemed to have beneficial ownership of the
securities held by the Dylan Trust. Mr. Hixon disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.


Represents an award of restricted stock, pursuant to Rule 16b-3, which will vest in two equal annual installments beginning July 15, 2026, and finally vesting in full on July 15, 2027. The number of shares was determined by dividing $75,000 by the closing price of the Company's Class D shares on July 15, 2025. The closing price of the Class D shares on that date was $0.607.

The total represents all shares held by the reporting person across all classes of Urban One, Inc. stock, Classes A, B, C and D.

This filing corresponds to non-employee directors grants made July 15, 2025. Filings for other directors were made on July 17, 2025 and Mr. McNeill's filing was attempted to be made on that date but was delayed due to credentialing errors requiring the re-enrollment of Mr. McNeill under the Form ID system as updated March 24, 2025.


Shares increased by 55.867 shares since the date of the reporting person's last filing due to additional shares acquired through dividends reinvested since the reporting person's last Form filing.

Kenneth R. Urmie, Deputy Corporate Secretary, for Jennifer L. Hauschildt under Power of Attorney dated April 27, 2023


Includes 7,324 restricted shares that vest monthly in equal installments through April 1, 2027, 11,436 restricted stock units that vest on 2/22/2027, 11,069 restricted stock units that vest on 2/16/2026,
and 100,596 shares owned outright.

Represents shares held of record by the Gregg Sengstack 2020 Dynasty Trust, for which the reporting person's spouse is the trustee and over which the reporting person does not have sole voting and investment power.

Represents shares held of record by the Dianne Sengstack 2020 Dynasty Trust, for which the reporting person is the trustee and over which the reporting person has sole voting and investment power.

Represents shares held of record by the Sengstack Family Foundation, for which the reporting person is the president and over which the reporting person has sole voting and dispositive power.

Jonathan M. Grandon, power of attorney for Gregg C. Sengstack


Common Stock - Voting

Common Stock - Voting

Dividend Reinvestment

Each share of phantom stock represents the right to receive one share of Common Stock - Voting.  Shares of Phantom Stock are payable in shares of Common Stock - Voting in accordance with the terms of the Non-Qualified Retirement Savings Plan.


Common Stock - Voting

Common Stock - Voting

Dividend Reinvestment.


First BanCorp Common Stock, par value $0.10 per share

This amount represents the weighted average sale price for the shares, which were sold in multiple transactions on Augsut 12, 2025 at prices ranging from $20.90 to $21.055.Thereporting person undertakes to provide to First BanCorp, any security holder of First BanCorp, or the staff of the Securities and Exchange Commission, upon request,fullinformation regarding the number of shares sold at each separate price within the ranges set forth in footnote (1).

/s/ Adolfo Sepulveda, Esq., Attorney-in-Fact


The purchase was made in Swiss Francs at a price of CHF 39.87 per share, and converted into US Dollars using the transaction date exchange rate of (USD 1.00 = CHF 0.8034).


Common Stock

The option is fully vested.

Awarded pursuant to the Entegris, Inc. 2010 Stock Plan in consideration of services as an employee.

/s/ Joseph Colella, Attorney-In-Fact for Susan G. Rice


Common Stock

This amendment (this "Amendment") is being filed to correct the number of shares beneficially owned following reported transaction as reported in the Form 4 filed with the Securities and Exchange Commission on August 11, 2025. According to the Original Form 4, the Reporting Person beneficially owned 93,319.964 shares of Daktronics, Inc. common stock. In fact, as reported in this Amendment, the Reporting Person owned 104,693.926 shares of Daktronics, Inc. common stock following the reported transaction.

Incentive Stock Options 20% vested each year for a total of five years - vesting schedule 8/23/2016, 8/23/2017, 08/23/2018, 08/23/2019, 08/23/2020.


Common Stock

This amendment (this "Amendment") is being filed to correct the acquisition of Daktronics, Inc. common stock ("Common Stock") reported on the Form 4 filed with the Securities and Exchange Commission on August 11, 2025 (the "Original Form").  According to the Original Form it reflected a disposal of 6,870 shares by the Reporting Person. In fact, as reported in this Amendment, the Reporting Person acquired 6,870 of Common Stock.


Der units credited on 06/03/2025 at FMV

26.1716 shares withheld to satisfy tax liability


On August 12, 2025, the reporting person received 20,675 shares from his mother's estate.

On August 12, 2025, the trust received 2,449 shares from the reporting person's mother's estate.

/s/ Stephanie J. Pacitti, attorney-in-fact for Richard F. Stepan


The transaction indicated was conducted under an approved 10b5-1 Plan, adoption date of referenced 10b5-1(c) plan is: 12-06-2024.

/s/ Tracy Feanny, Attorney in Fact For: Tonya Stevens


Common Stock

Common Stock

On August 12, 2025, the reporting person received 20,676 shares from his mother's estate.

The reporting person disclaims beneficial ownership of these securities, except to extent of any pecuniary interest in the shares.

Shares held by an estate of which the reporting person serves as executor.

On August 12, 2025, the trust received 2,448 shares from the reporting person's mother's estate.

Joint Tenancy with Spouse.

Share Units are acquired under the Management Incentive Plan ("MIP"), a nonqualified deferred compensation plan that allows participants to defer all or a portion of their annual incentive awards.

Share Units convert on a one-for-one basis into Common Stock.

Share Units are generally payable at end of employment, unless otherwise elected.

/s/ Stephanie J. Pacitti, Attorney-in-Fact for F. Quinn Stepan, Jr.


Common Stock

Common Stock

Includes shares of restricted stock which vest in three equal annual installments commencing on December 19, 2023.

Includes shares of restricted stock which vest in three equal annual installments commencing on December 16, 2024.

Includes shares of restricted stock which vest in three equal annual installments commencing on December 9, 2025.

Includes shares of restricted stock which vest in three equal annual installments commencing on December 19, 2026.

Includes shares of restricted stock which vest in three equal annual installments commencing on December 3, 2027.

Includes shares of restricted stock which vest in three equal annual installments commencing on December 15, 2027.

Stock options are fully vested.

/s/ Eric S. Bader, pursuant to Power of Attorney


/s/ Victor L. Cangelosi, pursuant to Power of Attorney


Includes shares of common stock acquired under the reporting person's Employee Stock Ownership Plan (ESOP) account through August 12, 2025.

This Form 4 reports the gift of shares by the reporting person.
santellipoa.txt

/s/ Jonathan N. Santelli by Jonathan J. Doyle as Attorney-in-Fact


This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2025, by and among the Issuer, Mist Holding Co. ("Parent"), and MD BE Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, effective as of August 12, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.01 per share, of the Company ("Common Stock") issued and outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive $5.34 in cash, without interest (the "Merger Consideration").

Includes 11,686 shares of restricted stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock award corresponding to shares of Common Stock that was outstanding and unvested as of immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of Common Stock corresponding to such award of restricted stock immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, less applicable withholding taxes.


Common Stock, $0.01 par value

Includes 11,199 shares of restricted stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock award corresponding to shares of Common Stock that was outstanding and unvested as of immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of Common Stock corresponding to such award of restricted stock immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, less applicable withholding taxes.

The securities are held in the account of 121G, LLC (the "Holder") and may be deemed to be beneficially owned by Wyche "Tee" Green, III, the managing member of the holder.

The Issuer effected a 1-for-15 reverse stock split of its common stock on October 4, 2024. The number of securities reported on this Form 4 has been adjusted to reflect the reverse stock split.

Pursuant to the terms of the Merger Agreement, at the Effective Time, each warrant to purchase shares of Common Stock (each, a "Company Warrant") that was outstanding and unexercised and had a per share exercise price that was less than the Merger Consideration was canceled and converted into the right to receive (i) a cash payment equal to (A) the number of shares of Common Stock subject to the Company Warrant immediately prior to the Effective Time multiplied by (B) the excess, if any, of (x) the Merger Consideration over (y) the exercise price per share of Common Stock of such Company Warrant, less applicable withholding taxes. Each Company Warrant that was outstanding and unexercised with a per share exercise price that was equal to or greater than the Merger Consideration was canceled for no consideration.


Includes 13,712 shares of restricted stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock award corresponding to shares of Common Stock that was outstanding and unvested as of immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of Common Stock corresponding to such award of restricted stock immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, less applicable withholding taxes.


*Includes shares issued pursuant to the dividend reinvestment plan.


Includes 9,499 shares of restricted stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock award corresponding to shares of Common Stock that was outstanding and unvested as of immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of Common Stock corresponding to such award of restricted stock immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, less applicable withholding taxes.


Common Stock, $0.01 par value

Includes 4,833 shares owned by spouse.


Common Stock, $0.01 par value


Reflects shares withheld upon vesting of restricted stock units to satisfy tax withholding obligations.

/s/ Chris Scholla, by Dathan C. Voelter as Attorney-in-Fact


Common Stock, $0.01 par value

The securities are held in the account of Tamarack Advisers, LP (the "Holder") and may be deemed to be beneficially owned by Justin J. Ferayorni, the managing member of the general parter of the Holder.

The reported securities are owned directly by The Ferayorni Family Trust for which Mr. Ferayorni serves as co-trustee.


Common Stock, par value $0.001 per share

Mr. Miller is the owner of the MSSB C/F David Nathan Miller IRA, which owns the reported securities


Common Stock

Each restricted stock unit represents a contingent right to receive one share of FXNC common stock.

The restricted stock units vest in one installment, with 5,000 vesting on 12/31/2027.

/s/ Christopher L Sugg, by Power of Attorney


By The Smith 2012 Spousal Trust uad 12/03/2012

By Kaye DeHaven Smith Irrevocable Trust FBO Elise D. Smith (Daughter)

By The Smith 2012 GST Trust uad 12/03/2012

The reporting person serves as a co-trustee of this trust.

The reporting person's spouse serves as trustee of this trust.

The reporting person's spouse serves as co-trustee of this trust.

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or any other purpose.

The reporting person serves as trustee of this trust.